ZEBRA: a phase 2 trial of zanubrutinib and rituximab in people with mantle cell lymphoma
This trial aims to see how effective zanubrutinib is when given with rituximab in people with mantle cell lymphoma (MCL)
You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT05635162
Trial aim and background The aim of this trial is to assess whether early treatment with zanubrutinib when given in combination with rituximab in people with low-grade (slow growing) MCL is beneficial when compared to observation. It will also assess whether it is safe and well tolerated.
People in the trial will be divided randomly into two groups. The experimental group will receive zanubrutinib and rituximab, while the control group will be observed. People in the experimental group will receive up to 6 cycles of treatment. You will not be able to choose what group you are in.
Who can enter
Adults with MCL which is classed as low-grade and have not received any prior treatment may be eligible for this trial.
Locations
Recruitment is taking place at the following UK locations:
- Clatterbridge Cancer Centre, Liverpool
- St Bartholomew's Hospital, London
- University College London Hospital, London
- Christie Hospital, Manchester
- Churchill Hospital, Oxford
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05635162
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.